Efficacy and Safety of Trastuzumab Deruxtecan and Nivolumab as Third- or Later-Line Treatment for HER2-Positive Advanced Gastric Cancer: A Single-Institution Retrospective Study

PURPOSE: Determination of optimal treatment strategies for HER2-positive advanced gastric cancer (AGC) in randomized trials is necessary despite difficulties in direct comparison between trastuzumab deruxtecan (T-DXd) and nivolumab as third or later-line treatments. MATERIALS AND METHODS: This singl...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimozaki, Keitaro, Nakayama, Izuma, Takahari, Daisuke, Nagashima, Kengo, Yoshino, Koichiro, Fukuda, Koshiro, Fukuoka, Shota, Osumi, Hiroki, Ogura, Mariko, Wakatsuki, Takeru, Ooki, Akira, Shinozaki, Eiji, Chin, Keisho, Yamaguchi, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Gastric Cancer Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630565/
https://www.ncbi.nlm.nih.gov/pubmed/37932227
http://dx.doi.org/10.5230/jgc.2023.23.e41

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630565/
https://www.ncbi.nlm.nih.gov/pubmed/37932227
http://dx.doi.org/10.5230/jgc.2023.23.e41

Ejemplares similares